



Frontiers in Vaccines for COVID-19 and Related Coronavirus Diseases

Guest Editor:

Dr. Sarah R. Leist

Department of Epidemiology,
University of North Carolina at
Chapel Hill, Chapel Hill, NC
27599, USA

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editor

Dear Colleagues,

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been identified as the causative agent of Coronavirus Disease 2019 (COVID-19). The virus was first reported in Wuhan, China, and subsequently rapidly spread around the world, leading to one of the most severe pandemics in human history. By January 2021, more than 94 million confirmed cases have been reported in 191 countries and territories, and more than 2,029 million people have died. Worldwide efforts to stop transmission of SARS-CoV-2 and end the pandemic did not succeed in eradicating the virus, yet. Therefore, the development of effective intervention and prevention strategies is of uttermost importance.

This Special Issue focuses on the following aspects:

1. Development of vaccines against COVID-19 and other coronaviruses
2. Factors influencing vaccine performance and outcome (e.g. environmental, comorbidities, gender).

Dr. Sarah R. Leist

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)